Literature DB >> 31229291

The involvement of GM-CSF deficiencies in parallel pathways of pulmonary alveolar proteinosis and the alcoholic lung.

William S Slovinsky1, Freddy Romero1, Dominic Sales1, Hoora Shaghaghi1, Ross Summer2.   

Abstract

Chronic alcohol consumption renders the lung more susceptible to infections by disrupting essential alveolar macrophage functions. Emerging evidence suggests that these functional deficits are due, in part, to a suppression of GM-CSF signaling, which is believed to compromise monocyte growth and maturation in the lung. However, in addition to controlling monocyte behaviors, GM-CSF also regulates surfactant homeostasis. For example, mice with targeted deletion of the gene for GM-CSF accumulate large amounts of surfactant phospholipids in their lungs. Moreover, decreased GM-CSF signaling in humans has been linked to the development of pulmonary alveolar proteinosis (PAP), a rare disorder in which surfactant lipids and proteins accumulate in alveolar macrophages and the lung exhibits enhanced susceptibility to infection. Consistent with parallel mechanisms in the PAP and alcoholic lung, we have recently reported that levels of intrapulmonary lipids, specifically triglycerides and free fatty acids, are increased in BAL fluid, whole lung digests and alveolar macrophages of chronically alcohol exposed rats. Additionally, we showed that uptake of saturated fatty acids alone could induce phenotypic and functional changes in alveolar macrophages that mimicked those in the alcohol-exposed rat and human lung. Herein, we discuss the role of GM-CSF in surfactant homeostasis and highlight the evidence that links decreased GM-CSF signaling to alveolar macrophage dysfunction in both the PAP and alcohol-exposed lung. Moreover, we discuss how lipid accumulation itself might contribute to altering alveolar macrophage function and propose how targeting these mechanisms could be employed for reducing the susceptibility to pulmonary infections in alcoholics.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Acute respiratory distress syndrome; Alcohol use disorder; GM-CSF; Metabolism; Pneumonia; Pulmonary surfactant

Year:  2018        PMID: 31229291      PMCID: PMC6592783          DOI: 10.1016/j.alcohol.2018.07.006

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  59 in total

Review 1.  Macrophage polarization in pathology.

Authors:  Antonio Sica; Marco Erreni; Paola Allavena; Chiara Porta
Journal:  Cell Mol Life Sci       Date:  2015-07-26       Impact factor: 9.261

2.  GM-CSF Induces Inflammatory Macrophages by Regulating Glycolysis and Lipid Metabolism.

Authors:  Yi Rang Na; Gyo Jeong Gu; Daun Jung; Young Won Kim; Juri Na; Jin Sun Woo; Joo Youn Cho; Hyewon Youn; Seung Hyeok Seok
Journal:  J Immunol       Date:  2016-10-14       Impact factor: 5.422

3.  Fatty acid transfer from intestinal fatty acid binding protein to membranes: electrostatic and hydrophobic interactions.

Authors:  Betina Córsico; Gisela R Franchini; Kuo-Tung Hsu; Judith Storch
Journal:  J Lipid Res       Date:  2005-05-01       Impact factor: 5.922

4.  SP-D and GM-CSF regulate surfactant homeostasis via distinct mechanisms.

Authors:  M Ikegami; W M Hull; M Yoshida; S E Wert; J A Whitsett
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-09       Impact factor: 5.464

5.  Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis.

Authors:  M S Kavuru; E J Sullivan; R Piccin; M J Thomassen; J K Stoller
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

6.  Alcohol-induced lipid change in th lung.

Authors:  D F Liau; S A Hashim; R N Pierson; S F Ryan
Journal:  J Lipid Res       Date:  1981-05       Impact factor: 5.922

Review 7.  Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis.

Authors:  Nora Anderson; Jürgen Borlak
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

8.  Targeted PPAR{gamma} deficiency in alveolar macrophages disrupts surfactant catabolism.

Authors:  Anna D Baker; Anagha Malur; Barbara P Barna; Shobha Ghosh; Mani S Kavuru; Achut G Malur; Mary Jane Thomassen
Journal:  J Lipid Res       Date:  2010-01-11       Impact factor: 5.922

9.  Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis.

Authors:  Tracey L Bonfield; Carol F Farver; Barbara P Barna; Anagha Malur; Susamma Abraham; Baisakhi Raychaudhuri; Mani S Kavuru; Mary Jane Thomassen
Journal:  Am J Respir Cell Mol Biol       Date:  2003-06-12       Impact factor: 6.914

10.  Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis.

Authors:  Anagha Malur; Mani S Kavuru; Irene Marshall; Barbara P Barna; Isham Huizar; Reema Karnekar; Mary Jane Thomassen
Journal:  Respir Res       Date:  2012-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.